{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$5.85 vs. cons $5.66",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Net revenues (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$4.55B vs. cons $4.52B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Acute Care same-facility adjusted admissions growth (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~+1.0% vs. cons +2.8%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$23.35 (range $23.25-23.50) vs. cons $23.44 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Net revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$18.5B vs. cons $18.54B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "ACA exchange subsidy pretax headwind",
      "prediction": "LOWER",
      "answer": "guide ~$90M vs. prior guide $75M (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Core (ex-DPP) EBITDA growth target",
      "prediction": "UNKNOWN",
      "answer": "guide ~reaffirmed +5% vs. prior/consensus-implied +5% (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -4.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -4.5,
  "day5_path": "STABILIZE",
  "day5_rationale": "Prior two prints (Q4'25 -11.4%, Q1'26 -9.5%) showed diverging 5-day behavior: Q4 saw continued sell-side estimate cuts and follow-through (~-6% more into day5) as core/DPP quality concerns spread, while Q1 stabilized within days (residual flattened to ~0% by day5) once the initial repricing captured the core-growth/ACA skepticism. Heading into Q2, expectations are already de-risked (Zacks Rank #4, 0% ESP, stock down ~30% YTD, up 6.4% into the print), a modestly worse ACA headwind guide and still-soft core volumes are largely anticipated rather than a fresh negative surprise, and constructive peer prints (HCA, THC) plus ongoing buybacks at depressed prices should limit incremental post-print estimate cuts, favoring stabilization over cascading follow-through.",
  "day5_confidence": "LOW"
}